EA201891366A1 - Гуманизированные антитела против cd73 - Google Patents

Гуманизированные антитела против cd73

Info

Publication number
EA201891366A1
EA201891366A1 EA201891366A EA201891366A EA201891366A1 EA 201891366 A1 EA201891366 A1 EA 201891366A1 EA 201891366 A EA201891366 A EA 201891366A EA 201891366 A EA201891366 A EA 201891366A EA 201891366 A1 EA201891366 A1 EA 201891366A1
Authority
EA
Eurasian Patent Office
Prior art keywords
humanized antibodies
antibodies against
present
humanized
relates
Prior art date
Application number
EA201891366A
Other languages
English (en)
Inventor
Эмили Пиччоне Грифифин
Ричард А. Миллер
Герхард Йоханн Фрэй
Хваи Вэнь Чан
Original Assignee
Корвус Фармасьютикалз, Инк.
БАЙОАТЛА, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Корвус Фармасьютикалз, Инк., БАЙОАТЛА, ЭлЭлСи filed Critical Корвус Фармасьютикалз, Инк.
Publication of EA201891366A1 publication Critical patent/EA201891366A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится, среди прочего, к гуманизированным антителам 1E9, способным связывать CD73. Гуманизированные антитела можно использовать для лечения злокачественных опухолей. Кроме того, настоящее изобретение относится к нуклеиновым кислотам, кодирующим гуманизированные антитела 1E9, и к способам ингибирования пролиферации клеток с использованием гуманизированных антител, представленных в настоящем описании.
EA201891366A 2015-12-09 2016-12-09 Гуманизированные антитела против cd73 EA201891366A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562265357P 2015-12-09 2015-12-09
US201662289694P 2016-02-01 2016-02-01
US201662346327P 2016-06-06 2016-06-06
PCT/US2016/065968 WO2017100670A1 (en) 2015-12-09 2016-12-09 Humanized anti-cd73 antibodies

Publications (1)

Publication Number Publication Date
EA201891366A1 true EA201891366A1 (ru) 2018-12-28

Family

ID=59013359

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891366A EA201891366A1 (ru) 2015-12-09 2016-12-09 Гуманизированные антитела против cd73

Country Status (13)

Country Link
US (2) US10822426B2 (ru)
EP (1) EP3387442A4 (ru)
JP (2) JP7391510B2 (ru)
KR (1) KR20180134837A (ru)
CN (2) CN109154611B (ru)
AU (1) AU2016366548B2 (ru)
CA (1) CA3007646A1 (ru)
CL (1) CL2018001512A1 (ru)
EA (1) EA201891366A1 (ru)
IL (1) IL259927B2 (ru)
MX (1) MX2018006973A (ru)
WO (1) WO2017100670A1 (ru)
ZA (1) ZA201803874B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7391510B2 (ja) 2015-12-09 2023-12-05 コーバス・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｄ７３抗体
EP3481869A4 (en) * 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. ANTI-CD73 ANTIBODY
UA126571C2 (uk) 2017-01-24 2022-11-02 Ай-Маб Байофарма Юес Лімітед Антитіло до cd73 та його застосування
JP7308150B2 (ja) 2017-03-16 2023-07-13 イナート・ファルマ・ソシエテ・アノニム 癌を処置するための組成物及び方法
EP3606962A4 (en) * 2017-04-04 2020-12-23 Corvus Pharmaceuticals, Inc. TREATMENT METHODS FOR HIGH CD73 TUMORS
WO2019068907A1 (en) 2017-10-06 2019-04-11 Innate Pharma RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
CN110240654A (zh) * 2018-03-07 2019-09-17 复旦大学 结合cd73的抗体-药物偶联物
MX2020009394A (es) 2018-03-09 2021-01-15 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos.
KR20200128542A (ko) * 2018-03-09 2020-11-13 페인스 테라퓨틱스 인코포레이티드 항-cd73 항체 및 이의 용도
CN111918873A (zh) 2018-03-27 2020-11-10 百时美施贵宝公司 使用紫外线信号实时监测滴度
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CN112334486A (zh) 2018-06-18 2021-02-05 先天制药公司 用于治疗癌症的组合物和方法
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
CA3118706A1 (en) * 2018-11-05 2020-05-14 Corvus Pharmaceuticals, Inc. B-cell activating cd73 antibodies
AU2019381219A1 (en) * 2018-11-12 2021-05-27 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD73 antibody, antigen-binding fragment thereof and application thereof
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
TWI790445B (zh) * 2019-06-06 2023-01-21 大陸商北京加科思新藥研發有限公司 對cd73具有特異性的結合分子及其用途
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP3999545A4 (en) * 2019-08-21 2023-09-13 Harbour Biomed (Shanghai) Co., Ltd ANTI-CD73 ANTIBODIES AND USE THEREOF
KR20220057558A (ko) 2019-09-06 2022-05-09 심포젠 에이/에스 항-cd73 항체
EP4051713A4 (en) * 2019-11-01 2024-05-01 Corvus Pharmaceuticals, Inc. ANTI-CD73 IMMUNOMODULATING ANTIBODIES AND THEIR USES
MX2022007573A (es) 2020-01-03 2022-09-23 Incyte Corp Terapia de combinación de inhibidor de grupo de diferenciación 73 (cd73) e inhibidor del receptor de adenosina a2a/a2b.
CA3166533A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Anti-cd73 antibodies and uses thereof
BR112022021397A2 (pt) * 2020-04-22 2023-02-07 Akeso Biopharma Inc Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma
CN115867582A (zh) * 2020-05-29 2023-03-28 朝途生物疗法株式会社 抗cd73抗体及其用途
EP4169948A1 (en) 2020-06-22 2023-04-26 Innovent Biologics (Suzhou) Co., Ltd. Anti-cd73 antibody and use thereof
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
TW202222840A (zh) * 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
AU2021411952A1 (en) 2020-12-29 2023-08-10 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2022179039A1 (zh) * 2021-02-24 2022-09-01 苏州近岸蛋白质科技股份有限公司 抗人cd73抗体及其应用
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN115991772B (zh) * 2022-08-12 2023-09-01 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024116140A1 (en) 2022-12-01 2024-06-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
CN116813786A (zh) * 2023-08-03 2023-09-29 贝达药业股份有限公司 抗cd73抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
CA2487321A1 (en) * 2002-06-17 2003-12-24 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels
AU2008266951B2 (en) * 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2010042562A2 (en) * 2008-10-06 2010-04-15 Minerva Biotechnologies Corporation Muc1* antibodies
WO2011091078A2 (en) * 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN103068852B (zh) * 2010-08-17 2016-04-20 弗·哈夫曼-拉罗切有限公司 抗人IgG1抗体
AU2012279288B2 (en) 2011-07-01 2017-07-20 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
WO2014130965A1 (en) * 2013-02-22 2014-08-28 Amgen Inc. Gastrokine-1 (gkn1) binding proteins and methods of treatment
WO2014153424A1 (en) * 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
WO2015070972A1 (en) * 2013-11-12 2015-05-21 Atlab Pharma Human igg1 derived antibody with pro-apoptotic activity
US10131704B2 (en) 2014-04-25 2018-11-20 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
EP3259288A1 (en) * 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
JP7391510B2 (ja) 2015-12-09 2023-12-05 コーバス・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｄ７３抗体

Also Published As

Publication number Publication date
IL259927B2 (en) 2023-05-01
IL259927A (en) 2018-07-31
CN109154611A (zh) 2019-01-04
JP2019503709A (ja) 2019-02-14
JP2022104941A (ja) 2022-07-12
CA3007646A1 (en) 2017-06-15
CL2018001512A1 (es) 2019-03-08
KR20180134837A (ko) 2018-12-19
US10822426B2 (en) 2020-11-03
EP3387442A1 (en) 2018-10-17
CN109154611B (zh) 2022-04-08
IL259927B1 (en) 2023-01-01
MX2018006973A (es) 2019-05-16
AU2016366548B2 (en) 2023-12-14
US20190077873A1 (en) 2019-03-14
CN114805575A (zh) 2022-07-29
ZA201803874B (en) 2020-11-25
EP3387442A4 (en) 2019-05-08
WO2017100670A1 (en) 2017-06-15
US20210253727A1 (en) 2021-08-19
JP7391510B2 (ja) 2023-12-05
US11859007B2 (en) 2024-01-02
AU2016366548A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
EA201891366A1 (ru) Гуманизированные антитела против cd73
EA202091540A1 (ru) Антитела к lilrb2
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
NZ738008A (en) Tigit-binding agents and uses thereof
WO2016144728A3 (en) Anti-lilrb antibodies and their use in detecting and treating cancer
MX2018005550A (es) Anticuerpos que se unen especificamente a tim-3 y sus usos.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790413A1 (ru) Антитела против tigit
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
EA201591791A1 (ru) Антитела pac1 человека
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
PH12018500203A1 (en) Anti-cd154 antibodies and methods of using them
EA201690992A1 (ru) Антитела, специфичные к fcrn
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
WO2017041092A3 (en) Anti-survivin antibodies for cancer therapy